Urgent

Renal AL amyloidosis

AL amyloid · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Deposition of monoclonal immunoglobulin light-chain-derived amyloid fibrils in the kidney causing nephrotic-range proteinuria and progressive renal failure, usually from an underlying plasma cell clone. Rapid diagnosis and clone-directed therapy improve organ and overall survival.

Red flags

  • Cardiac involvement (raised troponin/NT-proBNP, heart failure, arrhythmia)
  • Rapidly rising creatinine or heavy proteinuria
  • Hypotension/autonomic failure
  • Severe nephrotic syndrome with thrombosis
  • Gastrointestinal bleeding or malabsorption (systemic amyloid)

Assessment

Differential diagnosis

  • AL (light-chain) amyloidosis
  • AA (serum amyloid A) amyloidosis
  • Monoclonal immunoglobulin deposition disease
  • Diabetic nephropathy (other nephrotic cause)
  • Primary membranous nephropathy
  • Hereditary amyloidosis

Investigations

  • Serum/urine electrophoresis and serum free light chains with ratio
  • Urine ACR/PCR (often nephrotic-range) and renal function
  • Serum albumin, NT-proBNP/troponin (cardiac involvement)
  • Renal (or other tissue) biopsy with Congo red staining and amyloid typing (mass spectrometry)
  • Bone marrow biopsy for plasma cell clone
  • Echocardiogram/cardiac MRI for cardiac amyloid

Management

  • Suspect in unexplained nephrotic-range proteinuria, especially with cardiac or multisystem features
  • Screen for a monoclonal protein with serum/urine electrophoresis and serum free light chains
  • Confirm amyloid histologically (Congo red apple-green birefringence) and, critically, type it (mass spectrometry) to distinguish AL from AA/hereditary
  • Assess organ involvement, especially cardiac (NT-proBNP, troponin, echo) which dominates prognosis
  • Identify the underlying plasma cell/B-cell clone with bone marrow biopsy
  • Refer urgently to haematology for clone-directed therapy (bortezomib-based regimens, often with daratumumab)
  • Consider autologous stem cell transplantation in selected fit patients
  • Provide supportive nephrology care: RAAS blockade, BP and oedema management, nephrotic complication prophylaxis
  • Monitor haematological response (free light chains) and organ response
  • Manage cardiac amyloid carefully (avoid hypotension, cautious diuretics, arrhythmia risk)
  • Plan renal replacement therapy if end-stage disease develops
  • Coordinate specialist amyloidosis centre follow-up

Drugs & doses

Bortezomib-based regimen (e.g. daratumumab-bortezomib-cyclophosphamide-dexamethasone) per haematology
Dexamethasone (component of clone-directed therapy, dosed per protocol)
Ramipril 2.5-10 mg PO daily (nephroprotection, as tolerated by BP)
Furosemide titrated for nephrotic oedema (cautious if cardiac amyloid)
Anticoagulation/thromboprophylaxis for nephrotic hypercoagulability per risk

Disposition

Joint nephrology-haematology (national amyloidosis centre) management. Urgent clone-directed therapy. Cardiology input for cardiac involvement; transplant only after clonal control.

Complications & pitfalls

  • Progressive renal failure
  • Cardiac amyloid with heart failure and sudden death
  • Nephrotic complications (thrombosis, infection)
  • Autonomic neuropathy and hypotension
  • Treatment toxicity
  • Recurrence in transplanted kidney if clone untreated

Exam pearls

  • Typing amyloid (AL vs AA vs hereditary) changes treatment entirely — never assume AL
  • Cardiac involvement dominates prognosis — always assess the heart
  • Serum free light chains are both diagnostic and a treatment-response marker
  • Clone-directed haematology therapy, not just supportive care, is essential
  • Be cautious with diuretics and antihypertensives in cardiac amyloid (hypotension risk)

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.